NAS:CORT Key Ratios
| Market Cap $ M | 12,193.50 |
| Enterprise Value $ M | 11,894.72 |
| P/E(ttm) | 268.57 |
| PE Ratio without NRI | 268.57 |
| Forward PE Ratio | 26.29 |
| Price/Book | 17.25 |
| Price/Sales | 15.75 |
| Price/Free Cash Flow | 128.89 |
| Price/Owner Earnings | 811.53 |
| Payout Ratio % | -- |
| Revenue (TTM) $ M | 830.00 |
| EPS (TTM) $ | 0.42 |
| Beneish M-Score | -2.58 |
| 10-y EBITDA Growth Rate % | -- |
| 5-y EBITDA Growth Rate % | -11.90 |
| y-y EBITDA Growth Rate % | -98.00 |
| EV-to-EBIT | 1,857.10 |
| EV-to-EBITDA | 1,347.84 |
| PEG | -- |
| Shares Outstanding M | 108.10 |
| Net Margin (%) | 6.64 |
| Operating Margin % | 0.77 |
| Pre-tax Margin (%) | 3.17 |
| Quick Ratio | 2.77 |
| Current Ratio | 2.86 |
| ROA % (ttm) | 6.62 |
| ROE % (ttm) | 8.47 |
| ROIC % (ttm) | 1.41 |
| Dividend Yield % | -- |
| Altman Z-Score | 41.60 |
CORT Number of Guru Trades
CORT Volume of Guru Trades
Gurus Latest Trades with NAS:CORT
NAS:CORT is held by these investors
Corcept Therapeutics Inc Insider Transactions
Guru Commentaries on NAS:CORT
Corcept Therapeutics (CORT) reported a successful Phase III result for an ovarian cancer treatment and was rewarded handsomely. This positive outcome highlights the company's potential for growth and value creation in the health care sector, particularly in oncology, which is a critical area of focus. The successful trial results not only enhance Corcept's market position but also contribute to the overall performance of the Small Cap Quality Growth portfolio, indicating strong confidence in its future prospects.
Corcept Therapeutics Inc. (CORT) had a negative impact on performance as the fund did not own the stock. The stock rose sharply at quarter end after management reported positive results from the phase three study of ROSELLA, an ovarian cancer treatment. However, the fund's lack of exposure to this stock was detrimental, indicating a missed opportunity in a potentially strong investment.
News about NAS:CORT
Total 0- 1
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
